Table 2 Associations between the risk score and characteristics of HCC patients in training cohort.
Characteristic | Low-risk group (n = 124) | High-risk group (n = 123) | P value |
|---|---|---|---|
Age, median (IQR) | 61 (51, 69) | 61 (52, 69) | 0.924 |
BMI, meidan (IQR) | 25.65 (23.36, 30.12) | 23.42 (20.94, 27.45) |  < 0.001 |
Gender, n (%) | Â | Â | 0.966 |
Female | 38 (30.6%) | 39 (31.7%) | Â |
Male | 86 (69.4%) | 84 (68.3%) | Â |
Family cancer history, n (%) | Â | Â | 0.736 |
Yes | 38 (35.5%) | 37 (32.5%) | Â |
No | 69 (64.5%) | 77 (67.5%) | Â |
Race, n (%) | 122 | 119 | 0.360 |
American Indian or Alaska native | 0 (0%) | 1 (0.8%) | Â |
Asian | 56 (45.9%) | 56 (47.1%) | Â |
Black or African American | 3 (2.5%) | 7 (5.9%) | Â |
White | 63 (51.6%) | 55 (46.2%) | Â |
Alcohol consumption, n (%) | Â | 118 | 0.392 |
Yes | 38 (32.8%) | 46 (39.0%) | Â |
No | 78 (67.2%) | 72 (61.0%) | Â |
Hepatitis B, n (%) | Â | Â | 0.224 |
Yes | 41 (35.3%) | 32 (27.1%) | Â |
No | 75 (64.7%) | 86 (72.9%) | Â |
Hepatitis C, n (%) | Â | Â | 0.533 |
Yes | 18 (15.5%) | 14 (11.9%) | Â |
No | 98 (84.5%) | 104 (88.1%) | Â |
T stage, n (%) | Â | Â | 0.031 |
T1 | 71 (57.7%) | 51 (41.5%) | Â |
T2 | 29 (23.6%) | 30 (24.3%) | Â |
T3 | 19 (15.4%) | 35 (28.5%) | Â |
T4 | 3 (2.4%) | 7 (5.7%) | Â |
TX | 1 (0.8%) | 0 (0%) | Â |
N stage, n (%) | Â | Â | 0.945 |
N0 | 85 (68.4%) | 82 (67.2%) | Â |
N1 | 1 (0.8%) | 1 (0.8%) | Â |
NX | 38 (30.6%) | 39 (32.0%) | Â |
M stage, n (%) | Â | Â | 0.711 |
M0 | 91 (73.4%) | 86 (69.9%) | Â |
M1 | 1 (0.8%) | 2 (1.6%) | Â |
MX | 32 (25.8%) | 35 (28.5%) | Â |
Pathologic stage, n (%) | Â | Â | 0.013 |
Stage I | 69 (59.0%) | 49 (42.6%) | Â |
Stage II | 28 (23.9%) | 27 (23.5%) | Â |
Stage III | 18 (15.4%) | 37 (32.2%) | Â |
Stage IV | 2 (1.7%) | 2 (1.7%) | Â |
Neoplasm histologic grade, n (%) |  |  |  < 0.001 |
G1 | 23 (18.9%) | 10 (8.3%) | Â |
G2 | 65 (53.3%) | 53 (43.8%) | Â |
G3 | 33 (27.0%) | 49 (40.5%) | Â |
G4 | 1 (0.8%) | 9 (7.4%) | Â |
Child–pugh classification grade, n (%) |  |  | 0.787 |
A | 86 (93.5%) | 61 (91.0%) | Â |
B | 6 (6.5%) | 6 (9.0%) | Â |
Microvascular invasion, n (%) | Â | Â | 0.113 |
Yes | 33 (29.2%) | 39 (40.6%) | Â |
None | 80 (70.8%) | 57 (59.4%) | Â |
